About this study
Acute myeloid leukemia (AML) is a kind of cancer that starts in the bone marrow. The bone marrow lies inside the large bones of the body and makes blood cells. Some of these cells can change and become abnormal, grow quickly, and crowd out the normal blood cells so they do not work as they should. AML treatment usually uses chemotherapy drugs to kill the leukemia cells.
In this study, scientists will add a drug called venetoclax to chemotherapy to treat newly diagnosed AML in children and young adults. Scientists hope that venetoclax will help improve the chances of long-term remission (no evidence of leukemia) in these patients. The U.S. Food and Drug Administration (FDA) has approved venetoclax to treat adults with AML. The drug has not yet been approved to treat AML in children.
A previous study found that venetoclax was safe and active when given to children who had AML that came back (relapsed) or resisted other treatments.
Eligibility overview
- Newly diagnosed with AML
- Older than 28 days and younger than 22 years
- No earlier treatment for AML
- Not pregnant
- Using birth control if capable of having children